Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Disclosure furnished under Regulation FD, generally not subject to Exchange Act Section 18 liability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.